Literature DB >> 27840362

Current Diagnosis and Management of Thyroid Nodules.

Tjokorda Gde Dalem Pemayun1.   

Abstract

Thyroid nodules are frequently found. Although they are often palpable, many are found incidentally during unrelated radiographic studies. Ten to 15% of thyroid nodules represents thyroid malignancy. Clinician suc as an internist/endocrinologist have to  classify the nodule, stratify the risk of thyroid cancer, performed a diagnostic work-up, provide medical / non-surgical therapy, select candidates for surgery and provide appropriate follow-up that should last a lifetime. This article provide an up-date review of diagnostic approach and management of thyroid nodules, focusing on current algorithm in lights of the most recent published American Thyroid Association thyroid nodule and differentiated thyroid cancer management guidelines.

Entities:  

Keywords:  management; therapy; thyroid cancer; thyroid nodule

Mesh:

Year:  2016        PMID: 27840362

Source DB:  PubMed          Journal:  Acta Med Indones        ISSN: 0125-9326


  23 in total

1.  NPSR1-AS1 activates the MAPK pathway to facilitate thyroid cancer cell malignant behaviors via recruiting ELAVL1 to stabilize NPSR1 mRNA.

Authors:  Tiangen Ni; Dan Guo; Ling Tan; Zhesi Xiao; Yanjie Shi
Journal:  Cell Cycle       Date:  2022-01-14       Impact factor: 4.534

2.  The value of color Doppler ultrasound in the diagnosis of thyroid nodules: a systematic review and meta-analysis.

Authors:  Danbo Zhao; Yi Jing; Xiaoyi Lin; Bixia Zhang
Journal:  Gland Surg       Date:  2021-12

3.  Clinical value of SMI Combined with Low-Dose CT Scanning in differential diagnosis of Thyroid Lesions and Tumor Staging.

Authors:  Shao-Wei Xue; Yu-Kun Luo; Zi-Yu Jiao; Lin Xu
Journal:  Pak J Med Sci       Date:  2021 Sep-Oct       Impact factor: 1.088

4.  The application value of CDFI and SMI combined with serological markers in distinguishing benign and malignant thyroid nodules.

Authors:  Fang Li; Wei Sun; Lihua Liu; Zhen Meng; Jianli Su
Journal:  Clin Transl Oncol       Date:  2022-07-06       Impact factor: 3.340

5.  MicroRNA-338-3p inhibits thyroid cancer progression through targeting AKT3.

Authors:  Guo-Qing Sui; Dan Fei; Feng Guo; Xi Zhen; Qiang Luo; Shuai Yin; Hui Wang
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

6.  Down-regulation and clinical significance of miR-7-2-3p in papillary thyroid carcinoma with multiple detecting methods.

Authors:  Hua-Yu Wu; Yi Wei; Shang-Ling Pan
Journal:  IET Syst Biol       Date:  2019-10       Impact factor: 1.615

Review 7.  The emerging function and clinical significance of circRNAs in Thyroid Cancer and Autoimmune Thyroid Diseases.

Authors:  Yu Zhang; Dong-Dong Jia; Yi-Fei Zhang; Meng-Die Cheng; Wen-Xiu Zhu; Pei-Feng Li; Yin-Feng Zhang
Journal:  Int J Biol Sci       Date:  2021-04-17       Impact factor: 6.580

8.  miR-622 suppresses tumor formation by directly targeting VEGFA in papillary thyroid carcinoma.

Authors:  Qingjie Ma; Qiang Wen; Renjie Wang; Linlin Ji; Yue Yao; Mengshi Ma
Journal:  Onco Targets Ther       Date:  2018-03-16       Impact factor: 4.147

9.  Predictor Analysis in Radiofrequency Ablation of Benign Thyroid Nodules: A Single Center Experience.

Authors:  Alessandro Bisceglia; Ruth Rossetto; Sara Garberoglio; Angelica Franzin; Alice Cerato; Francesca Maletta; Mauro Giulio Papotti; Ezio Ghigo; Loredana Pagano; Mauro Maccario; Roberto Garberoglio
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-17       Impact factor: 5.555

10.  MicroRNA-26a-5p inhibits proliferation, invasion and metastasis by repressing the expression of Wnt5a in papillary thyroid carcinoma.

Authors:  Dongliang Shi; Haiyan Wang; Mingjian Ding; Meng Yang; Chenhao Li; Wenhua Yang; Liang Chen
Journal:  Onco Targets Ther       Date:  2019-08-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.